All News

Do you increase spacing of TNF-i administration in your patients with axSpA with sustained low disease activity for one year? OP0138 results showed similar relapse rates in those with increased spacing intervals and those on standard dosing regimen. #EULAR2021 @RheumNowNews

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Does Guselkumab (IL23-i) modulate gene expression in #PsA? Dr Siebert analysed samples from DISCOVER RCTs & reported normalisation of⬆️regulated genes (e.g. Neutrophil,monocyte) and ⬇️regulated (B-,T- and NK cells) signatures by GUS post-therapy #EULAR2021 #POS0195 @RheumNow https://t.co/2qtpxrrwkF
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
AVN in SLE is ⬇️ing over time! risks are same: younger, male, glucocorticoids & also found hyperlipidemia. ?due to older age of onset & less steroids over time & better immune suppressants POS0730 @RheumNow #EULAR2021 @eular_org https://t.co/IG3NVrZl4D
Janet Pope Janetbirdope ( View Tweet)
Once approved, what type of patients with #SLE would you treat with #anifrolumab? #EULAR2021 #OP0131 @RheumNow

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

Sjogren’s QoL reported dryness correlates with objective salivary flow ⭐️lower perceived dryness associated with higher immunologic activity Abs#POS0102 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

#EULAR2021 OP0138 - Radiographic AxSpA in LDA, SPACING anti-TNF vs continue care. 83% were able to ⬆️ dosing interval at month 12, drug efficacy recovered in pts with relapsed disease. Worth trying in stable patient who wants to wean down meds. @RheumNow

Eric Dein ejdein1 ( View Tweet)

Do patients with #SpA have a different phenotype if they have "root joint disease"? Find out at the #EULAR2021 Poster Tour #POS0239 or at https://t.co/30JdHxTKus https://t.co/ocEefm8II9

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
@AurelieRheumo @RheumNow Looks like modern art and not a prediction model. Lots of scatter in data by my untrained eyes! @RheumNow #EULAR2021

Janet Pope Janetbirdope ( View Tweet)

@MeralElRamahiMD @RheumNow True that axSpA is diff from pts with peripheral SpA predominantly but isn’t it circular reasoning to say axial has more HLAB27+ as that is group in whom criteria were developed including HLAB27?

Janet Pope Janetbirdope ( View Tweet)

Poorer outcomes with #JAKi in pts who get #SARSCoV2 but ? related to line of therapy - worse off if 2nd line advanced Rx in RA vs 1st line? JAKi has short half life so it washes out? And..#baricitinib added to #remdesivir improves outcomes NEJM @RheumNow #EULAR2021 #OP0006 Dunno! https://t.co/583z6Mlw3y

Links:

Janet Pope Janetbirdope ( View Tweet)

Do we need to monitor #ECG in patients on #HCQ and #polypharmacy? Dr Antivalle reported ⬆️QTc interval in HCQ vs controls. Only 3/132 was above ULN in HCQ group though. Importantly,⬆️QTc was noted more in HCQ + co-meds (e.g. PPI) #EULAR2021 #POS0090 @RheumNow https://t.co/1Ui4MghqIk
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Don’t forget to use imaging that you already have! CT Abd/Pelvis (ordered for nonMSK) of 301 IBD pts shows underlying sacroilitis ⭐️60/301 had sacroilitis on CT ⭐️11/60 had AxSpA ⭐️3/60 previously undiagnosed axSpA Abs#POS0035 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

➡️ASTERA = PIII trial that showed superior efficacy of Netakimab (IL-17Ai) vs PBO in pts w/ active r-axSpA. Excluded pts prev tx w/ 2 or more TNFi ➡️OP0142 = sub-analysis showing Netak ⬇️ dz activity in AS pts irrespective of sacroillitis on MRI at b/l #EULAR2021 @Rheumnow https://t.co/faT3M0xQiR
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
I haven’t used it but… Netakimab (IL-17i) approved for treatment of PsO, AS, and PsA in Russia and Belarus ⭐️⬇️AS activity w/ or w/o MRI sacroilitis Abs#OP0142 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

Bingo. It always had been rather odd to me that you would call someone nr-SpA when they had MR evidence of disease; xrays are not sensitive to pick up changes. While we're at it, can we just use the term "imaging" instead of "radiographs" with the availability of better tech? https://t.co/I6reoHyywf

Links:

k dao KDAO2011 ( View Tweet)

Filgotinib showed ⬇️ in spinal inflammation of AS pts after 12 weeks! ⭐️Subscores of the posterior elements, facet joints and vertebral bodies showed significant changes ⭐️no significant changes in spine fat, bone erosion or new bone formation Abs#OP0141 #EULAR2021 @RheumNow https://t.co/tcBFuxnu4n
Robert B Chao, MD doctorRBC ( View Tweet)
Fatigue 35-80% of rheumatic pts! Excellent talk on fatigue in arthritis, SpA and systemic rheumatic disease! Abs#OP6875 #EULAR2021 @RheumNow How do you help pts manage fatigue?

Robert B Chao, MD doctorRBC ( View Tweet)

➡️COMPLETE-AS = obs study of bDMARD-naive Canadians w/ active AS tx w/ ADA or nbDMARDS/NSAID. ➡️> overall⬇️in dz burden & shorter time to achieve therapeutic response w/ ADA. But, ADA pts had higher b/l dz OP0143 #EULAR2021 @RheumNow https://t.co/FpJmugsdVw
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD ⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD ⭐️No overall increase in all CA: RTX, TOCI ⭐️Abatacept 1.21HR for all cancer, mainly NMSC ⭐️needs more data on JAKs, IL-17, IL-23 Abs#6916 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

Efficacy & Safety of UPA after 1yr from SELECT-AXIS 1 study? ⭐️187 bDMARD-naive, active AS pts w/ inadeq resp to NSAID ⭐️82-85% txed w/ UPA 15mg QD achieved BASDAI50 or ASDAS LDA over 64w 🚫 new safety signal & ZERO VTE, MACE, TB, or deaths w/ UPA. OP0144 #EULAR2021 @RheumNow https://t.co/mFbgQjsD6f
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
×